SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 38781962.
- Also identified by DOI 10.1016/j.xcrm.2024.101583 and PMC identifier 11228552.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Little is known about the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or SARS2) vaccine breakthrough infections (BTIs) on the magnitude and breadth of the T cell repertoire after exposure to different variants. We studied samples from individuals who experienced symptomatic BTIs during Delta or Omicron waves. In the pre-BTI samples, 30% of the donors exhibited substantial immune memory against non-S (spike) SARS2 antigens, consistent with previous undiagnosed asymptomatic SARS2 infections. Following symptomatic BTI, we observed (1) enhanced S-specific CD4 and CD8 T cell responses in donors without previous asymptomatic infection, (2) expansion of CD4 and CD8 T cell responses to non-S targets (M, N, and nsps) independent of SARS2 variant, and (3) generation of novel epitopes recognizing variant-specific mutations. These variant-specific T cell responses accounted for 9%-15% of the total epitope repertoire. Overall, BTIs boost vaccine-induced immune responses by increasing the magnitude and by broadening the repertoire of T cell antigens and epitopes recognized.
Medical subject headings
- SARS-CoV-2
- COVID-19
- Epitopes, T-Lymphocyte
- CD8-Positive T-Lymphocytes
- CD4-Positive T-Lymphocytes
- COVID-19 Vaccines